Events
-
-
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
ASCO 2026: Phase 3 PEAK study could usher in new second-line therapy for GIST
-
ASCO 2026: Personalised vaccine boosts immune activity against brain cancer
-
ASCO 2026: GLP-1s may reduce metastatic progression of certain obesity-related cancers
-
ASCO 2026: Yoga may help cancer survivors sleep better and reduce anxiety, fatigue
-
-
Powerful new tool promises major advances in cancer treatment
New Australian technology is set to transform the way that gastrointestinal cancers are detected and…
“Cytokine factory” implant: triggers immune response in metastatic melanoma, pancreatic and colorectal tumours
A team of researchers from Rice University has developed an implantable “cytokine factory” that safely…
Midlife comorbidities and their impact on cancer incidence and mortality
A recent cohort study published in JAMA Network Open explores the associations between various midlife…
Socioeconomic lung cancer study offers further evidence on importance of screening
- Hospital first-in-paediatrics to use technology that lights up lung cancer during surgery
- Centre initiates groundbreaking clinical trial with oncolytic virus for non-small cell lung cancer
- Smoking-related deaths could be reduced if people attending lung cancer screening are offered stop-smoking support
Te Aho o Te Kahu releases Analysis of Cancer Medicine Availability in Aotearoa
Today we are releasing our analysis of cancer medicine availability in New Zealand Aotearoa, Understanding the Gap: an analysis of…
JOIN THE ONCOLOGY NETWORK
If you would like even more free news articles, access to our exclusive HCP only content including the latest podcasts from The Oncology Podcast and our Industry Partner Podcasts (including links to all papers and show notes), along with all our other resources, head over to The Oncology Network and sign up - FREE forever for HCPs only.